ENEST | Learn About Novartis Oncology

Search this website :

Home

About Novartis Oncology – Evaluating Nilotinib Efficacy and Safety in Clinical Trials

About Novartis Oncology Header Image of Couple

At Novartis Oncology, our employees worldwide share a common mission: discover and develop innovative medicines to fight cancer. Headquartered in Florham Park, New Jersey, we are passionate about providing a broad range of new remedies and practical solutions that change the way patients live with cancer.

With more than 4,500 employees operating in over 50 countries, Novartis Oncology has a truly global reach. We have the advantage of extraordinarily talented and globally diverse employees who, through shared goals and different perspectives, are dedicated to improving and extending the lives of patients around the world.

We have a proven track record of providing new and improved cancer treatments and are continually discovering and developing new therapies that change lives. We are currently concentrating efforts on research platforms spanning discoveries in signal transduction inhibition, cytotoxic agents, antiangiogenesis, cell cyle/apoptosis, iron chelation, metastases and hormone therapy.

Learn more at NovartisOncology.com.



Disclaimer: This is intended for healthcare professionals. This is an international website for the ENEST (Evaluating Nilotinib Efficacy and Safety in Clinical Trials) program. The information on this site is not country-specific and may contain ENEST program information that is different from where you practice. Please contact your local Novartis representative for the latest ENEST information specific to your country. The compound NILOTINIB described in this site has been approved in a number of countries for Ph+ CML; it has not been approved in any countries for KIT+ GIST. If NILOTINIB has not yet been approved in your country, there is no guarantee that NILOTINIB will become commercially available.